Skip to content

Author

Osman Bilge Kaya

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Mucosal, Ocular, and Pulmonary Adverse Events Reported with Datopotamab Deruxtecan: An Indication-Restricted Disproportionality Analysis of the FDA Adverse Event Reporting System

Background/Objectives: Datopotamab deruxtecan was approved in 2025 for hormone receptor-positive, HER2-negative metastatic breast cancer and for EGFR-mutated non-small cell lung cancer (NSCLC); its safety profile in routine use has not been described. We characterized adverse event reporting for the agent and asked whe...

Osman Bilge Kaya, B. Karabuğa, E. Aydemir et al. · 0 citations
Open access Oct 2026

Distinct NGS mutational landscape and prognostic implications in early-onset colorectal cancer: A dual-cohort analysis of TCGA PanCancer Atlas and MSK-IMPACT 50K

Background Early-onset colorectal cancer (EOCRC), defined as CRC diagnosed before age 50, is rising globally. The genomic landscape of EOCRC has been characterized in several prior studies, but the reproducibility of findings across independent cohorts, the impact of adjustment for tumor stage and sample type, and the...

Elif Sertesen Çamöz, Osman Bilge Kaya, Hakan Erçelebi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.